http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 16 Jun 2026 16:45:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++20-FA+++++NovaBridge+Biosciences++++For%3A+Dec+31/26654833.html si-local-file:///var/storage/secattach/20260616/26654833.html http://www.streetinsider.com/SEC+Filings/Form++20-FA+++++NovaBridge+Biosciences++++For%3A+Dec+31/26654833.html Tue, 16 Jun 2026 16:45:00 -0400 NBP O.38348529 http://www.streetinsider.com/SEC+Filings/Form++20-FA+++++NovaBridge+Biosciences++++For%3A+Dec+31/26654833.html si-local-file:///var/storage/secattach/20260616/26654833.html http://www.streetinsider.com/SEC+Filings/Form++20-FA+++++NovaBridge+Biosciences++++For%3A+Dec+31/26654833.html Tue, 16 Jun 2026 16:45:00 -0400 NBP O.38348529 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Jun+16/26654726.html si-local-file:///var/storage/secattach/20260616/26654726.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Jun+16/26654726.html Tue, 16 Jun 2026 16:40:00 -0400 NBP O.38348529 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Jun+16/26654726.html si-local-file:///var/storage/secattach/20260616/26654726.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Jun+16/26654726.html Tue, 16 Jun 2026 16:40:00 -0400 NBP O.38348529 http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+NOVABRIDGE+drug+for+gastric+cancer/26650262.html <p>NovaBridge Biosciences (NASDAQ: NBP) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to givastomig, a CLDN18.2 x 4-1BB bispecific antibody, in combination with nivolumab and chemotherapy for the treatment of previously untreated HER2-negative advanced or metastatic gastroesophageal adenocarcinomas in patients whose tumors are both CLDN18.2 and PD-L1 positive.</p> <p>Fast Track Designation is intended to facilitate development and expedite review of therapies for serious conditions with unmet medical need. Programs receiving the designation may be eligible for Rolling Review, Priority Review, and Accelerated Approval if relevant criteria are met.</p> <p>The company said a registrational Phase 3 trial is http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+NOVABRIDGE+drug+for+gastric+cancer/26650262.html Tue, 16 Jun 2026 07:00:43 -0400 A.06822034 NBP O.20026344 O.38348529 http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+NOVABRIDGE+drug+for+gastric+cancer/26650262.html <p>NovaBridge Biosciences (NASDAQ: NBP) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to givastomig, a CLDN18.2 x 4-1BB bispecific antibody, in combination with nivolumab and chemotherapy for the treatment of previously untreated HER2-negative advanced or metastatic gastroesophageal adenocarcinomas in patients whose tumors are both CLDN18.2 and PD-L1 positive.</p> <p>Fast Track Designation is intended to facilitate development and expedite review of therapies for serious conditions with unmet medical need. Programs receiving the designation may be eligible for Rolling Review, Priority Review, and Accelerated Approval if relevant criteria are met.</p> <p>The company said a registrational Phase 3 trial is http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+NOVABRIDGE+drug+for+gastric+cancer/26650262.html Tue, 16 Jun 2026 07:00:43 -0400 A.06822034 NBP O.20026344 O.38348529 http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+NOVABRIDGE+drug+for+gastric+cancer/26650262.html <p>NovaBridge Biosciences (NASDAQ: NBP) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to givastomig, a CLDN18.2 x 4-1BB bispecific antibody, in combination with nivolumab and chemotherapy for the treatment of previously untreated HER2-negative advanced or metastatic gastroesophageal adenocarcinomas in patients whose tumors are both CLDN18.2 and PD-L1 positive.</p> <p>Fast Track Designation is intended to facilitate development and expedite review of therapies for serious conditions with unmet medical need. Programs receiving the designation may be eligible for Rolling Review, Priority Review, and Accelerated Approval if relevant criteria are met.</p> <p>The company said a registrational Phase 3 trial is http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+NOVABRIDGE+drug+for+gastric+cancer/26650262.html Tue, 16 Jun 2026 07:00:43 -0400 A.06822034 NBP O.20026344 O.38348529 http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+NOVABRIDGE+drug+for+gastric+cancer/26650262.html <p>NovaBridge Biosciences (NASDAQ: NBP) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to givastomig, a CLDN18.2 x 4-1BB bispecific antibody, in combination with nivolumab and chemotherapy for the treatment of previously untreated HER2-negative advanced or metastatic gastroesophageal adenocarcinomas in patients whose tumors are both CLDN18.2 and PD-L1 positive.</p> <p>Fast Track Designation is intended to facilitate development and expedite review of therapies for serious conditions with unmet medical need. Programs receiving the designation may be eligible for Rolling Review, Priority Review, and Accelerated Approval if relevant criteria are met.</p> <p>The company said a registrational Phase 3 trial is http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+NOVABRIDGE+drug+for+gastric+cancer/26650262.html Tue, 16 Jun 2026 07:00:43 -0400 A.06822034 NBP O.20026344 O.38348529 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Jun+16/26650240.html si-local-file:///var/storage/secattach/20260616/26650240.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Jun+16/26650240.html Tue, 16 Jun 2026 07:00:00 -0400 NBP O.38348529 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Jun+16/26650240.html si-local-file:///var/storage/secattach/20260616/26650240.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NovaBridge+Biosciences++++For%3A+Jun+16/26650240.html Tue, 16 Jun 2026 07:00:00 -0400 NBP O.38348529 http://www.streetinsider.com/Press+Releases/NovaBridge+Biosciences+Receives+FDA+Fast+Track+Designation+for+Givastomig+in+First-Line+HER2-Negative+Metastatic+Gastric+Cancer/26650246.html <ul type="disc"><li style="margin-bottom:6pt;">Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026</li><li style="margin-bottom:6pt;">Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026</li></ul> <p align="justify">ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to givastomig in combination with nivolumab and chemotherapy for the treatment of patients with previously untreated HER2-negative advanced http://www.streetinsider.com/Press+Releases/NovaBridge+Biosciences+Receives+FDA+Fast+Track+Designation+for+Givastomig+in+First-Line+HER2-Negative+Metastatic+Gastric+Cancer/26650246.html Tue, 16 Jun 2026 07:00:00 -0400 A.06822034 NBP O.20026344 O.38348529 http://www.streetinsider.com/Press+Releases/NovaBridge+Biosciences+Receives+FDA+Fast+Track+Designation+for+Givastomig+in+First-Line+HER2-Negative+Metastatic+Gastric+Cancer/26650246.html <ul type="disc"><li style="margin-bottom:6pt;">Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026</li><li style="margin-bottom:6pt;">Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026</li></ul> <p align="justify">ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to givastomig in combination with nivolumab and chemotherapy for the treatment of patients with previously untreated HER2-negative advanced http://www.streetinsider.com/Press+Releases/NovaBridge+Biosciences+Receives+FDA+Fast+Track+Designation+for+Givastomig+in+First-Line+HER2-Negative+Metastatic+Gastric+Cancer/26650246.html Tue, 16 Jun 2026 07:00:00 -0400 A.06822034 NBP O.20026344 O.38348529 http://www.streetinsider.com/Press+Releases/NovaBridge+Biosciences+Receives+FDA+Fast+Track+Designation+for+Givastomig+in+First-Line+HER2-Negative+Metastatic+Gastric+Cancer/26650246.html <ul type="disc"><li style="margin-bottom:6pt;">Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026</li><li style="margin-bottom:6pt;">Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026</li></ul> <p align="justify">ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to givastomig in combination with nivolumab and chemotherapy for the treatment of patients with previously untreated HER2-negative advanced http://www.streetinsider.com/Press+Releases/NovaBridge+Biosciences+Receives+FDA+Fast+Track+Designation+for+Givastomig+in+First-Line+HER2-Negative+Metastatic+Gastric+Cancer/26650246.html Tue, 16 Jun 2026 07:00:00 -0400 A.06822034 NBP O.20026344 O.38348529 http://www.streetinsider.com/Press+Releases/NovaBridge+Biosciences+Receives+FDA+Fast+Track+Designation+for+Givastomig+in+First-Line+HER2-Negative+Metastatic+Gastric+Cancer/26650246.html <ul type="disc"><li style="margin-bottom:6pt;">Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026</li><li style="margin-bottom:6pt;">Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026</li></ul> <p align="justify">ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to givastomig in combination with nivolumab and chemotherapy for the treatment of patients with previously untreated HER2-negative advanced http://www.streetinsider.com/Press+Releases/NovaBridge+Biosciences+Receives+FDA+Fast+Track+Designation+for+Givastomig+in+First-Line+HER2-Negative+Metastatic+Gastric+Cancer/26650246.html Tue, 16 Jun 2026 07:00:00 -0400 A.06822034 NBP O.20026344 O.38348529 http://www.streetinsider.com/Globe+Newswire/NovaBridge+Biosciences+Receives+FDA+Fast+Track+Designation+for+Givastomig+in+First-Line+HER2-Negative+Metastatic+Gastric+Cancer/26650246.html <ul type="disc"><li style="margin-bottom:6pt;">Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026</li><li style="margin-bottom:6pt;">Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026</li></ul> <p align="justify">ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to givastomig in combination with nivolumab and chemotherapy for the treatment of patients with previously untreated HER2-negative advanced http://www.streetinsider.com/Globe+Newswire/NovaBridge+Biosciences+Receives+FDA+Fast+Track+Designation+for+Givastomig+in+First-Line+HER2-Negative+Metastatic+Gastric+Cancer/26650246.html Tue, 16 Jun 2026 07:00:00 -0400 A.06822034 NBP O.20026344 O.38348529 http://www.streetinsider.com/Globe+Newswire/NovaBridge+Biosciences+Receives+FDA+Fast+Track+Designation+for+Givastomig+in+First-Line+HER2-Negative+Metastatic+Gastric+Cancer/26650246.html <ul type="disc"><li style="margin-bottom:6pt;">Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026</li><li style="margin-bottom:6pt;">Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026</li></ul> <p align="justify">ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to givastomig in combination with nivolumab and chemotherapy for the treatment of patients with previously untreated HER2-negative advanced http://www.streetinsider.com/Globe+Newswire/NovaBridge+Biosciences+Receives+FDA+Fast+Track+Designation+for+Givastomig+in+First-Line+HER2-Negative+Metastatic+Gastric+Cancer/26650246.html Tue, 16 Jun 2026 07:00:00 -0400 A.06822034 NBP O.20026344 O.38348529 http://www.streetinsider.com/Globe+Newswire/NovaBridge+Biosciences+Receives+FDA+Fast+Track+Designation+for+Givastomig+in+First-Line+HER2-Negative+Metastatic+Gastric+Cancer/26650246.html <ul type="disc"><li style="margin-bottom:6pt;">Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026</li><li style="margin-bottom:6pt;">Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026</li></ul> <p align="justify">ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to givastomig in combination with nivolumab and chemotherapy for the treatment of patients with previously untreated HER2-negative advanced http://www.streetinsider.com/Globe+Newswire/NovaBridge+Biosciences+Receives+FDA+Fast+Track+Designation+for+Givastomig+in+First-Line+HER2-Negative+Metastatic+Gastric+Cancer/26650246.html Tue, 16 Jun 2026 07:00:00 -0400 A.06822034 NBP O.20026344 O.38348529 http://www.streetinsider.com/Globe+Newswire/NovaBridge+Biosciences+Receives+FDA+Fast+Track+Designation+for+Givastomig+in+First-Line+HER2-Negative+Metastatic+Gastric+Cancer/26650246.html <ul type="disc"><li style="margin-bottom:6pt;">Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026</li><li style="margin-bottom:6pt;">Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026</li></ul> <p align="justify">ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to givastomig in combination with nivolumab and chemotherapy for the treatment of patients with previously untreated HER2-negative advanced http://www.streetinsider.com/Globe+Newswire/NovaBridge+Biosciences+Receives+FDA+Fast+Track+Designation+for+Givastomig+in+First-Line+HER2-Negative+Metastatic+Gastric+Cancer/26650246.html Tue, 16 Jun 2026 07:00:00 -0400 A.06822034 NBP O.20026344 O.38348529 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NovaBridge+Biosciences++++For%3A+May+30++Filed+by%3A+Xu+Cong+Claire/26593760.html si-local-file:///var/storage/secattach/20260602/26593760.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NovaBridge+Biosciences++++For%3A+May+30++Filed+by%3A+Xu+Cong+Claire/26593760.html Tue, 02 Jun 2026 18:47:00 -0400 NBP O.38348529 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NovaBridge+Biosciences++++For%3A+May+30++Filed+by%3A+Xu+Cong+Claire/26593760.html si-local-file:///var/storage/secattach/20260602/26593760.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NovaBridge+Biosciences++++For%3A+May+30++Filed+by%3A+Xu+Cong+Claire/26593760.html Tue, 02 Jun 2026 18:47:00 -0400 NBP O.38348529 http://www.streetinsider.com/Press+Releases/NovaBridge+to+Present+at+the+2026+Jefferies+Global+Healthcare+Conference/26560977.html <p align="justify">ROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that members of the Company’s senior management team will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026.</p> <p align="justify">Conference details are as follows:</p> <p align="justify"><strong>2026 Jefferies Global Healthcare Conference</strong><br/>Format: Company Presentation and one-on-one investor meetings<br/>Date: Thursday, June 4, 2026<br/>Presentation time: 3:10 PM ET</p> <p align="justify">Webcast Link: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ll7VYsqJUtjvH1sWZHoj7D3PdbfoU-osrSa2beQETREeQ6UNZoZ27gAgs0xM_y7WX50FaLFJ4uSbgKXOyE82SU_EsgkJ1OxYt9qDigMbcbnJno-h4tePtLodyNwovKxC6znZ_jwqvjGmWry3eQrH7g==" rel="nofollow" target="_blank">Here</a></p> <p align="justify">The http://www.streetinsider.com/Press+Releases/NovaBridge+to+Present+at+the+2026+Jefferies+Global+Healthcare+Conference/26560977.html Thu, 28 May 2026 07:00:00 -0400 A.50216777 NBP O.38348529 O.54516537 http://www.streetinsider.com/Press+Releases/NovaBridge+to+Present+at+the+2026+Jefferies+Global+Healthcare+Conference/26560977.html <p align="justify">ROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that members of the Company’s senior management team will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026.</p> <p align="justify">Conference details are as follows:</p> <p align="justify"><strong>2026 Jefferies Global Healthcare Conference</strong><br/>Format: Company Presentation and one-on-one investor meetings<br/>Date: Thursday, June 4, 2026<br/>Presentation time: 3:10 PM ET</p> <p align="justify">Webcast Link: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ll7VYsqJUtjvH1sWZHoj7D3PdbfoU-osrSa2beQETREeQ6UNZoZ27gAgs0xM_y7WX50FaLFJ4uSbgKXOyE82SU_EsgkJ1OxYt9qDigMbcbnJno-h4tePtLodyNwovKxC6znZ_jwqvjGmWry3eQrH7g==" rel="nofollow" target="_blank">Here</a></p> <p align="justify">The http://www.streetinsider.com/Press+Releases/NovaBridge+to+Present+at+the+2026+Jefferies+Global+Healthcare+Conference/26560977.html Thu, 28 May 2026 07:00:00 -0400 A.50216777 NBP O.38348529 O.54516537 http://www.streetinsider.com/Press+Releases/NovaBridge+to+Present+at+the+2026+Jefferies+Global+Healthcare+Conference/26560977.html <p align="justify">ROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that members of the Company’s senior management team will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026.</p> <p align="justify">Conference details are as follows:</p> <p align="justify"><strong>2026 Jefferies Global Healthcare Conference</strong><br/>Format: Company Presentation and one-on-one investor meetings<br/>Date: Thursday, June 4, 2026<br/>Presentation time: 3:10 PM ET</p> <p align="justify">Webcast Link: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ll7VYsqJUtjvH1sWZHoj7D3PdbfoU-osrSa2beQETREeQ6UNZoZ27gAgs0xM_y7WX50FaLFJ4uSbgKXOyE82SU_EsgkJ1OxYt9qDigMbcbnJno-h4tePtLodyNwovKxC6znZ_jwqvjGmWry3eQrH7g==" rel="nofollow" target="_blank">Here</a></p> <p align="justify">The http://www.streetinsider.com/Press+Releases/NovaBridge+to+Present+at+the+2026+Jefferies+Global+Healthcare+Conference/26560977.html Thu, 28 May 2026 07:00:00 -0400 A.50216777 NBP O.38348529 O.54516537 http://www.streetinsider.com/Press+Releases/NovaBridge+to+Present+at+the+2026+Jefferies+Global+Healthcare+Conference/26560977.html <p align="justify">ROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that members of the Company’s senior management team will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026.</p> <p align="justify">Conference details are as follows:</p> <p align="justify"><strong>2026 Jefferies Global Healthcare Conference</strong><br/>Format: Company Presentation and one-on-one investor meetings<br/>Date: Thursday, June 4, 2026<br/>Presentation time: 3:10 PM ET</p> <p align="justify">Webcast Link: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ll7VYsqJUtjvH1sWZHoj7D3PdbfoU-osrSa2beQETREeQ6UNZoZ27gAgs0xM_y7WX50FaLFJ4uSbgKXOyE82SU_EsgkJ1OxYt9qDigMbcbnJno-h4tePtLodyNwovKxC6znZ_jwqvjGmWry3eQrH7g==" rel="nofollow" target="_blank">Here</a></p> <p align="justify">The http://www.streetinsider.com/Press+Releases/NovaBridge+to+Present+at+the+2026+Jefferies+Global+Healthcare+Conference/26560977.html Thu, 28 May 2026 07:00:00 -0400 A.50216777 NBP O.38348529 O.54516537 http://www.streetinsider.com/Globe+Newswire/NovaBridge+to+Present+at+the+2026+Jefferies+Global+Healthcare+Conference/26560977.html <p align="justify">ROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that members of the Company’s senior management team will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026.</p> <p align="justify">Conference details are as follows:</p> <p align="justify"><strong>2026 Jefferies Global Healthcare Conference</strong><br/>Format: Company Presentation and one-on-one investor meetings<br/>Date: Thursday, June 4, 2026<br/>Presentation time: 3:10 PM ET</p> <p align="justify">Webcast Link: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ll7VYsqJUtjvH1sWZHoj7D3PdbfoU-osrSa2beQETREeQ6UNZoZ27gAgs0xM_y7WX50FaLFJ4uSbgKXOyE82SU_EsgkJ1OxYt9qDigMbcbnJno-h4tePtLodyNwovKxC6znZ_jwqvjGmWry3eQrH7g==" rel="nofollow" target="_blank">Here</a></p> <p align="justify">The http://www.streetinsider.com/Globe+Newswire/NovaBridge+to+Present+at+the+2026+Jefferies+Global+Healthcare+Conference/26560977.html Thu, 28 May 2026 07:00:00 -0400 A.50216777 NBP O.38348529 O.54516537